BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31688499)

  • 21.
    Dyrberg E; Hendel HW; Huynh THV; Klausen TW; Løgager VB; Madsen C; Pedersen EM; Pedersen M; Thomsen HS
    Eur Radiol; 2019 Mar; 29(3):1221-1230. PubMed ID: 30132104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can Ga-68 PSMA PET/CT replace conventional imaging modalities for primary lymph node and bone staging of prostate cancer?
    Esen T; Kılıç M; Seymen H; Acar Ö; Demirkol MO
    Eur Urol Focus; 2020 Mar; 6(2):218-220. PubMed ID: 31113757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of [
    Uprimny C; Svirydenka A; Fritz J; Kroiss AS; Nilica B; Decristoforo C; Haubner R; von Guggenberg E; Buxbaum S; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1873-1883. PubMed ID: 29766246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Ga-68 PSMA positron emission tomography/computerized tomography with Tc-99m MDP bone scan in prostate cancer patients.
    Uslu-Beşli L; Sağer S; Akgün E; Asa S; Şahin OE; Demirdağ Ç; Güner E; Khosroshahi BR; Karayel E; Pehlivanoğlu H; Aygün A; Uslu İ; Talat Z; Sönmezoğlu K
    Turk J Med Sci; 2019 Feb; 49(1):301-310. PubMed ID: 30761859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
    Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
    Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
    Odewole OA; Tade FI; Nieh PT; Savir-Baruch B; Jani AB; Master VA; Rossi PJ; Halkar RK; Osunkoya AO; Akin-Akintayo O; Zhang C; Chen Z; Goodman MM; Schuster DM
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1773-83. PubMed ID: 27091135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic performance of
    Zhang J; Shao S; Wu P; Liu D; Yang B; Han D; Li Y; Lin X; Song W; Cao M; Zhang J; Kang F; Qin W; Wang J
    Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):908-920. PubMed ID: 30635755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
    Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
    J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
    Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
    BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.
    Rauscher I; Maurer T; Beer AJ; Graner FP; Haller B; Weirich G; Doherty A; Gschwend JE; Schwaiger M; Eiber M
    J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does whole-body bone SPECT/CT provide additional diagnostic information over [18F]-FCH PET/CT for the detection of bone metastases in the setting of prostate cancer biochemical recurrence?
    de Leiris N; Leenhardt J; Boussat B; Montemagno C; Seiller A; Phan Sy O; Roux J; Laramas M; Verry C; Iriart C; Fiard G; Long JA; Descotes JL; Vuillez JP; Riou L; Djaileb L
    Cancer Imaging; 2020 Aug; 20(1):58. PubMed ID: 32787923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gallium-68-prostate-specific membrane antigen (
    van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L
    BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
    Perera M; Papa N; Roberts M; Williams M; Udovicich C; Vela I; Christidis D; Bolton D; Hofman MS; Lawrentschuk N; Murphy DG
    Eur Urol; 2020 Apr; 77(4):403-417. PubMed ID: 30773328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intraobserver and interobserver agreement for the interpretation of 68Ga-prostate-specific membrane antigen-I&T positron emission tomography/computed tomography imaging.
    Gültekin A; Yaylalı O; Şengöz T; Yüksel D; Şahin B
    Nucl Med Commun; 2019 Dec; 40(12):1250-1255. PubMed ID: 31584465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
    Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
    BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography?
    Kulkarni SC; Sundaram PS; Padma S
    Nucl Med Commun; 2020 Feb; 41(2):139-146. PubMed ID: 31714366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection Rate of
    Jilg CA; Drendel V; Rischke HC; Beck TI; Reichel K; Krönig M; Wetterauer U; Schultze-Seemann W; Meyer PT; Vach W
    J Nucl Med; 2019 Jul; 60(7):971-977. PubMed ID: 30683768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (
    Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ
    BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Sheikhbahaei S; Jones KM; Werner RA; Salas-Fragomeni RA; Marcus CV; Higuchi T; Rowe SP; Solnes LB; Javadi MS
    Ann Nucl Med; 2019 May; 33(5):351-361. PubMed ID: 30877561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective comparative study of
    Fonager RF; Zacho HD; Langkilde NC; Fledelius J; Ejlersen JA; Hendel HW; Haarmark C; Moe M; Mortensen JC; Jochumsen MR; Petersen LJ
    Acta Oncol; 2018 Aug; 57(8):1063-1069. PubMed ID: 29447047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.